Bruce D. Brydon

Mr. Brydon serves as Chairman of the Board and is a co-founder of Trimel. Mr. Brydon's 35-year career in commercial healthcare and pharmaceuticals reflects leadership in all aspects of the pharmaceutical industry, including biochemicals, clinical diagnostics, surgical supplies, product and technology development, manufacturing, regulatory affairs, registration, licensing, marketing and sales. In the late 1980s and early 1990s, Mr. Brydon served as President and Chairman of Beiersdorf Canada and President and Managing Director of Boehringer Mannheim (currently Roche). From January 1995 through November 2001, he served as Chief Executive Officer and a Director of Biovail Corporation, guiding the business through a period of more than $4.5 billion in shareholder equity growth and increasing annual revenue from $19.0 million to more than $580.0 million. Since retiring from Biovail Corporation in 2001, Mr. Brydon has held both public and private company Directorships.

John Friedrichsen

Mr. Friedrichsen is a Chartered Accountant and the Senior Vice President and Chief Financial Officer at FirstService Corporation. Mr. Friedrichsen has been actively involved in over 90 business acquisitions, integrations and numerous capital market transactions which have contributed to an increase in enterprise value for FirstService from $460 million to $1.5 billion and an increase in revenue from $200 million to over $2 billion.  FirstService Corporation is a global leader in the rapidly growing real estate services sector, providing a variety of services in commercial real estate, residential property management and property services.

Stephen Gregory

Mr. Gregory is the Lead Director of the Trimel Board of Directors.  Mr. Gregory is President, Chairman and the controlling shareholder of IsaiX Technologies, a privately held company headquartered in Montreal, with offices in the United States and England. IsaiX Technologies works extensively across a wide variety of industry segments and has ongoing business transactions with more than 100 companies in the pharmaceutical, finance, banking and insurance sectors. IsaiX Technologies provides and implements its clients with human development programs, medical writing and essential physician scheduling platforms.  Mr. Gregory is the President of the Quebec Chapter of the Canada Company and is a member of its executive Committee. Mr. Gregory also spearheads charitable endeavours for the children of Canadian soldiers serving overseas.

Rolf K. Reininghaus

Mr. Reininghaus is a co-founder of Trimel and serves as the company's Executive Director and as a Director. Prior to joining Trimel, Mr. Reininghaus was a Senior Vice President and a Director of Biovail Corporation and the President of Biovail Ventures. Prior to that time, Mr. Reininghaus was President of Biovail Pharmaceuticals Canada. Prior to his employment with Biovail Corporation, Mr. Reininghaus was the Marketing Manager of the Canadian operations of Miles Pharmaceuticals, a division of Bayer AG.

Jeffrey Sherman

Mr. Sherman is currently Chief Financial Officer of Pure Nickel Inc. (TSX: NIC), a nickel exploration company with one of the largest portfolios of nickel exploration properties in the world. His previous experience includes acting as Chief Financial Officer of Herbert A Watts Limited, a business services and customer relationship management company. Mr. Sherman implemented many process improvements and arranged the refinancing and subsequent sale of the company. Prior to that, Mr. Sherman was Chief Financial Officer at Visible Genetics Inc., a medical instrumentation and diagnostics company (NASDAQ: VGIN, subsequently acquired by Bayer Corporation).  He established financial control systems and managed administration and finance as the company grew and helped drive the company's Initial Public Offering on the Nasdaq public market, as well as two significant private placement financings. Mr. Sherman teaches strategy, risk management, finance and accounting and has authored numerous books on business and finance. He is a Certified Investment Manager, a Chartered Accountant, and has a Master of Business Administration from York University and Bachelor of Commerce from the University of Toronto.

Dr. D. Lorne Tyrrell

Dr. Tyrrell is the Canadian Institute of Health Research (CIHR)/Glaxo SmithKline Chair in Virology in the Department of Medical Microbiology and Immunology at the University of Alberta. Since 1986, he has focused his research on viral hepatitis. Supported by CIHR and Glaxo Canada, Dr. Tyrrell’s work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine - in 1998. Dr. Tyrrell holds 22 international patents for his studies on viral hepatitis. Dr. Tyrrell was Dean of the Faculty of Medicine and Dentistry from 1994 – 2004 at the University of Alberta and is currently the Chair of the Board of Directors of the Gairdner Foundation. The Canada Gairdner International Awards recognizes excellence in medical science research globally. Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), the FNG Starr Award of the Canadian Medical Association (2004), the Principal Award of the Manning Awards Foundation (2005) and the Queen Elizabeth II Diamond Jubilee Medal (2012). Dr. Tyrrell was appointed Officer of the Order of Canada in 2002. In April 2010, D. Lorne Tyrrell was appointed as the inaugural director of the Li Ka Shing Institute of Virology at the University of Alberta. On April 28, 2011, Dr. Tyrrell was inducted to the Canadian Medical Hall of Fame.